|
|
1.
|
SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. MedStar authors:
Year: 2019
Citation: - Journal of Translational Medicine. 17(1):429, 2019 12 26.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Baste N, Clayburgh D, Cohen EEW, Fountzilas G, Fujii T, Khaliq A, Kim ES, Lin D, Lipworth L, Mehlhorn H, Melillo G, Pai SI, Resteghini C, Shara N, Shire N, Stokes M, Twumasi-Ankrah P, Wang H, Wildsmith S, Zhang J
|
|
|
2.
|
IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer. MedStar authors: - Swain, Sandra M MedStar Health
Year: 2024
Citation: - Annals of Oncology. 35(7):630-642, 2024 Jul.
Department: - Associate Dean for Research Development
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
All authors: - Dent R, Andre F, Goncalves A, Martin M, Schmid P, Schutz F, Kummel S, Swain SM, Bilici A, Loirat D, Villalobos Valencia R, Im SA, Park YH, De Laurentis M, Colleoni M, Guarneri V, Bianchini G, Li H, Kirchmayer Machackova Z, Mouta J, Deurloo R, Gan X, Fan M, Mani A, Swat A, Cortes J
|
